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Abstract
Background: Oxidative stress plays an important role in the pathogenesis of disease, and the antioxidant
physiological effect of omega-3 from fish oil may lead to improvement of canine spontaneous osteoarthritis (OA).
Methods: In this prospective randomized, controlled, double-blinded study, we assessed haematological and
biochemical parameters in dogs with OA following supplementation with either a concentrated omega-3 deep sea
fish oil product or corn oil. Blood samples from 77 client-owned dogs diagnosed as having OA were taken before
(baseline) and 16 weeks after having orally ingested 0.2 ml/Kg bodyweight/day of deep sea fish oil or corn oil.
Circulating malondialdehyde (MDA), glutathione (GSH), non-transferrin bound iron (NTBI), free carnitine (Free-Car),
8-hydroxy-2-deoxyguanosine (8-OH-dG), and serum fatty acids, haemograms and serum biochemistry were
evaluated. Differences within and between groups from baseline to end, were analysed using repeated samples
T-test or Wilcoxon rank test and independent samples T-test or a Mann-Whitney test.
Results: Supplementation with fish oil resulted in a significant reduction from day 0 to day 112 in MDA (from 3.41 ± 1.34
to 2.43 ± 0.92 μmol/L; P < 0.001) and an elevation in Free-Car (from 18.18 ± 9.78 to 21.19 ± 9.58 μmol/L; P = 0.004)
concentrations, whereas dogs receiving corn oil presented a reduction in MDA (from 3.41 ± 1.34 to 2.41 ± 1.01 μmol/L;
P = 0.001) and NTBI (from −1.25 ± 2.17 to −2.31 ± 1.64 μmol/L; P = 0.002). Both groups showed increased (albeit not
significantly) GSH and 8-OH-dG blood values. Dogs supplemented with fish oil had a significant reduction in the
proportions of monocytes (from 3.84 ± 2.50 to 1.77 ± 1.92 %; P = 0.030) and basophils (from 1.47 ± 1.22 to 0.62 ± 0.62 %;
P = 0.012), whereas a significant reduction in platelets counts (from 316.13 ± 93.83 to 288.41 ± 101.68 × 109/L; P = 0.029),
and an elevation in glucose (from 5.18 ± 0.37 to 5.32 ± 0.47 mmol/L; P = 0.041) and cholesterol (from 7.13 ± 1.62 to
7.73 ± 2.03 mmol/L; P = 0.011) measurements were observed in dogs receiving corn oil.
Conclusions: In canine OA, supplementation with deep sea fish oil improved diverse markers of oxidative status in the
dogs studied. As corn oil also contributed to the reduction in certain oxidative markers, albeit to a lesser degree, there
was no clear difference between the two oil groups. No clinical, haematological or biochemical evidence of side effects
emerged related to supplementation of either oil. Although a shift in blood fatty acid values was apparent due to the
type of nutraceutical product given to the dogs, corn oil seems not to be a good placebo.
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Background
Alongside the importance of knowledge of canine dis-
eases in veterinary medicine, pet dogs have increasingly
been used as translational models for human diseases
such as osteoarthritis (OA).
The three joints predominantly affected in canine OA
are the hips, elbows and knees [1]. OA commonly oc-
curs as a consequence of hip and elbow dysplasia [2]. In
these cases, even though the genetic background might
be crucial for the development of joint mechanical in-
stability, years of genetic selection by dog breeders has
not reduced the incidence of the disease [3]. Factors
such as nutritional imbalance [4, 5], chronic inflamma-
tion [6, 7], ageing [8, 9] and obesity [10, 11] are linked
to the development of OA in dogs and in humans. These
factors are also associated with oxidative stress [12].
Structural, cellular and molecular alterations due to pro-
teoglycan breakdown and inflammation triggered by e.g.
IL-1 are present in the evolution of OA [13].
Osteoarthritis is a condition that causes pain, inflamma-
tion and stiffness in many joints. Non-steroidal anti-
inflammatory drugs (NSAIDs) and disease-modifying
anti-rheumatic drugs (DMARDs) are available today for
the treatment of inflammatory disorders; however, these
drugs have side effects. NSAIDs react by blocking the ac-
tivity of cyclooxygenases (COXs) during inflammation
[14]. COX is a bifunctional enzyme exhibiting both COX
and peroxidase activities [15]. While the COX component
converts arachidonic acid (AA) to a hydroperoxy-
endoperoxide, the peroxidase component reduces the en-
doperoxide to the corresponding alcohol, the precursor of
prostanoids, such as thromboxanes and prostaglandins
[16]. Many promising new treatment approaches for OA
are available. The search for more natural anti-
inflammatory agents that can selectively block the activity
of COX-2 during inflammation is ongoing, with enhanced
therapeutic effect and little or no side effects even with
prolonged usage high on the wish list. Scientists have pro-
vided new evidence that fish oil supplementation de-
creases the formation of pro-inflammatory prostanoids,
which, when produced in excess, increase inflammation in
various tissues and organs [17, 18]. Fish oil is rich in doco-
sahexaenoic acid (DHA) and eicosapentaenoic acid (EPA),
n-3 fatty acids that act as competitive substrates for the
enzymes of AA metabolism and its products [19].
Reactive oxygen species (ROS), associated with pro-
inflammatory cytokines and prostaglandins, have been
shown to play a deleterious role in the course of joint
diseases, leading to cartilage damage [20, 21] and pro-
gressive chronic inflammation [22, 23]. Comparable
changes in the synovia immune cellularity have been de-
scribed in dogs as those occurring in humans [24, 25].
An increased level of oxidation in the synovial fluid of
osteoarthritic joints has been observed [26, 27], and in-
creased activity of antioxidant enzymes has been associ-
ated with decreased viscosity of the synovial fluid [28].
Also, markers of oxidative stress and levels of antioxi-
dant enzymes change in the blood of human patients
and dogs with OA. These include serum catalase (CAT),
superoxide dismutase (SOD), glutathione (GSH) and
malondialdehyde (MDA) [29, 30].
Lipid metabolism in tissues affected by OA includes per-
oxidation reactions that link inflammation, oxidative stress
and cartilage/bone tissue damage [28]. Lipid peroxidation
may be involved in the clinical consequences of pain and
dysfunction in the joint [31, 32]. Thus, dietary lipid com-
position is an important issue. Fish oil supplements, rich
in omega-3 polyunsaturated fatty acids (PUFAs), e.g. EPA,
have been claimed to be beneficial in the treatment of dis-
eases such as rheumatoid arthritis [33]. After fish oil sup-
plementation, the omega-3 s EPA and DHA increased in
both plasma and neutrophil membranes of human
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patients exhibiting clinical improvement of OA [34]. Sup-
plementation of n-3 PUFA in cell culture studies as well
as in animal in vivo studies showed that cell proliferation
was inhibited by production of lipid peroxides [35, 36].
Omega-3-related inhibition of cell proliferation via lipid
peroxidation is helpful in conditions such as cancer, al-
though lipid peroxidation and formation of ROS are
thought to produce tissue damage [28]. Under in vitro
conditions using endothelial cells, omega-3 supplementa-
tion resulted in an indirect antioxidant effect, character-
ized by reduced formation of lipid peroxidation products
associated with direct superoxide scavenging, thus redu-
cing inflammation, as compared with supplementing with
other long-chain PUFAs [37].
Evidence suggests that omega-3 supplementation ben-
efits human patients [38–40] and dogs [41–44] suffering
from OA. Earlier in vitro studies have reported some
beneficial effects of omega-3 fatty acids on cartilage cell
inflammation and metabolism [45, 46] that are consist-
ent with clinical observations. In dogs, the quality and
mechanisms underlying nutraceutical therapy with
omega-3 oils are just beginning to be investigated.
This paper reports our findings on the circulating levels
of fatty acids, oxidative stress markers and antioxidant
molecules as well as blood counts and serum biochemistry
as outcome measures in a controlled double-blind clinical
trial designed to compare the effects of omega-3 fatty
acids and corn oil in dogs suffering from OA.
Methods
Data on the clinical parameters have been published
earlier [43], with a detailed description of the study
protocol, the inclusion criteria for dogs, the diet and the
supplements and the blood sampling protocol. The
materials and methods section here contains only a brief
description of the dogs and study design.
Dogs and ethics
Briefly, 77 dogs met the inclusion criteria of age of at
least one year, a body weight exceeding 18 kg, prede-
termined clinical signs of OA, a Helsinki chronic pain
index (HCPI) [47] of over 6 and a radiographic diag-
nosis of hip, knee or elbow OA. Exclusion criteria
were neurological deficits, articular infection, recent
trauma, pregnancy, lactation or the owner would not
comply with changing the dogs’ diet or with giving
the supplement on a daily basis. The dogs lived with
their owners during the entire study period, and gen-
erally had low physical activity due to their OA con-
dition. The owners of the dogs were instructed not to
give non-steroidal anti-inflammatory drugs (NSAIDs)
or other analgesics for the two weeks preceding the
baseline visit if possible, and not to give medication
containing Na-pentosan polysulphate for 30 days.
They were also required to sign an informed consent
form acknowledging that they could leave the study
at any time, without giving a reason. The study
protocol was approved by the Committee of Ethics of
the University of Helsinki and was conducted at the
Small Animal Hospital of the same University.
Study design and test products
The study was run as a double-blind, randomized clin-
ical trial with a treatment group (an omega-3 supple-
ment comprising a concentrated oil product from deep
sea fish) and a negative control group (corn oil), using
the CONSORT guidelines [48]. All dogs were evaluated
by radiographs, submitted to blood sampling, and
assigned to groups using a stratified computer-generated
four-block random list [43] using the HCPI pain severity
level and the diet as strata. The groups were statisti-
cally equal in total number of dogs, gender (also
whether castrated, sterilized or intact), mean body
weight, mean age and mean disease (OA) duration in
months at baseline [43]. All eligible dogs were started
on a diet of commercial dry food, which was either a
basic wheat/beef (Royal Canin® Croc) or a rice/lamb
sensitive formula containing no wheat, soy, beef, pre-
servatives or artificial colorants (Jahti & Vahti®). Both
foods had similar nutritional composition with no fish oil-
derived ω-3 fatty acids and a ω-6/ω-3 ratio of 11:1. Neither
food contained ingredients with a known positive effect
on OA.
At baseline, the dogs were evaluated clinically, as de-
scribed elsewhere [43], and had their blood samples col-
lected. The dogs started the supplement trial by
receiving a pharmaceutically cleaned dense deep sea fish
oil with added vitamin E (Doils® Joints, Nutraceuticoils,
Belgium) or corn oil (control) daily at the dose of
0.2 ml/Kg of body weight (BW) per os. Fish oil used in
this study was concentrated by molecular distillation
with a total omega-3 content of 63.6 % (Table 1). The
fish oil contained 450 mg of EPA, 100 mg of DHA and
27 mg of eicosatetraenoic acid (ETA) per ml, with a total
ω-3 content of 63.6 % of the total fatty acid content
(Table 1). The same manufacturer supplied the corn oil
with fish smell in identical containers to be used as a
control. The corn oil contained only 1 % of ω-3, mainly
α-linolenic acid (ALA), and no EPA, DHA or docosa-
pentaenoic acid (DPA) [43]. To avoid oxidation of the
fatty acids all dog owners were instructed to keep the oil
supplement with the cap tightly shut in a dark refriger-
ator at 4-8 °C. At the end of the trial, at week 16, the
dogs were again clinically evaluated [43] and blood sam-
ples were taken after an overnight fast. All outcome
evaluators (veterinarians and owners) and technical as-
sistants were blinded (Fig. 1).
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Fatty acid analysis
The fatty acid composition of the oil products used was
analysed by an international food testing laboratory
using a modified AOCS Ce 1c-89 method (Eurofins,
Raisio, Finland).
The fatty acid profile of the serum total lipids was ana-
lysed according to Seppänen-Laakso et al. [49]. Briefly,
the serum lipids were first extracted with chloroform:di-
methyl ether (2:1), then centrifuged at 3500 rpm. The
lower chloroform layer was separated and evaporated
overnight. Petroleum ether (0.5 ml) was added. The me-
thyl esters were formed by adding 1 ml of 0.5 M Na-
methylat and keeping the substance in a 50 °C water
bath for 10 min. The samples were neutralized with
1 ml of NaHSO4, and the fatty acid methyl esters were
extracted by adding 0.5 ml of petroleum ether. The sam-
ples were shaken for 10 min and centrifuged at
3500 rpm. The petroleum ether layer was analysed by
DANI GC 1000 gas chromatography with NB-351
0.32 mm× 25 m capillary column by HNU-Nordion Ltd.
(Helsinki, Finland). The column oven was programmed
from 120 °C to 236 °C at 5.9 °C/min. Identification was
based on retention times. Dietary fatty acid content was
used to evaluate the adherence of each owner to providing
the dogs’ respective supplement of fish oil or corn oil.
Blood counts and biochemical analysis
Venous blood samples from overnight fasting dogs were
taken at all three visits from the cephalic vein prior to
any clinical tests or sedation. Whole-blood EDTA sam-
ples were immediately used for blood counts. To obtain
plasma, part of the blood samples were taken in polypro-
pylene tubes containing EDTA or Li-heparin and centri-
fuged at 1000 × g for 15 min. For serum, the blood was
allowed to clot at room temperature for 30 min and then
centrifuged at 1000 × g for 15 min. All serum and
plasma samples were stored at −80 °C until analysed.
Complete blood counts were performed with an auto-
mated haematology multiparameter analyser adjusted for
animal-cell counting (Cell-Dyn 3700 System, ABBOTT
Diagnostics Division, ABBOTT Park, IL, USA). Blood
smears were stained with May-Grünwald-Giemsa, and
manual leucocyte differentials were determined by
counting 200 cells.
The activity of serum alanine aminotransferase (ALT,
EC 2.6.1.2 was measured according to the recommenda-
tions of the International Federation of Clinical Chemis-
try [50] and serum alkaline phosphatase (ALP, EC
3.1.3.1) activity according to the recommendations of
the Scandinavian Society for Clinical Chemistry and
Clinical Physiology [51]. Spectrophotometric methods
were used for the determination of serum albumin, chol-
esterol, creatinine, glucose, total protein, triglycerides
and urea. Analyses were performed by using a clinical
chemistry analyser (Konelab 30i, Thermo Fisher Scien-
tific, Vantaa, Finland).
Lipid peroxidation was determined by HPLC-based
TBARS modified assay [52] and reported as MDA-
equivalent. In brief, the malondialdehyde-thiobarbituric
acid complex formed under high temperature (100 °C)
and acidic conditions were injected onto the Spherisorb
ODS2 (C18 column); 5 μm, 250 × 3.2 mm with guard col-
umn (C8) and eluted with 65 %, 50 mM potassium phos-
phate buffer pH 7.0 and 35 % methanol at a flow rate of
1.0 ml/min and detected at a wavelength of 532 nm.
Blood reduced GSH was determined using Ellman’s re-
agent [53] and served/applied as a marker of the antioxi-
dant capacity of the organism. Briefly, an aliquot
(0.2 ml) of whole blood was combined with 10 % sulpho-
salicylic acid. After centrifugation at 12,000 rpm for
2 min in a Eppendorf centrifuge at 4 °C, the supernatant
was analysed spectrophotometrically at 412 nm, with
Table 1 Composition of fish oil and corn oil products used as
nutraceutical supplements for the study dogs suffering from
osteoarthritis
Component Fish oil
g/100 g
Corn oil
g/100 g
Analyzed fatty acids
Palmitic acid (PA), C16:0a 0.6 10.2
Stearic acid (SA), C18:0a 4.6 1.8
Oleic acid (OA), C18:1 ω-9b 9.7 28.6
Linoleic acid (LA), C18:2 ω-6c 1.3 51.8
Gamma-Linolenic acid (GLA), C18:3 ω-6c 0.7 0.1
Eicosadienoic acid (EDA), C20:2 ω-6c 0.3 0
Dihomo-gamma-linolenic acid (DHGLA), C20:3 ω-6c 0.4 0
Arachidonic acid (AA), C20:4 ω-6c 2.1 0
Palmitoleic acid (PO), C16:1 ω-7b 0.2 0.1
α-linolenic acid (ALA), C18:3 ω-3c 0.6 1.0
Stearidonic acid (SDA), C18:4 ω-3c 2.4 0
Eicosatetraenoic acid (ETA), C20:4 ω-3c 1.8 0
Eicosapentaenoic acid (EPA), C20:5 ω-3c 43.9 0
Docosapentaenoic acid (DPA), C22:5 ω-3c 2.2 0
Docosahexaenoic acid (DHA), C22:6 ω-3c 11.4 0
Other fatty acids combined 17.8 6.4
%
ω-3 fatty acids 63.6 1.0
ω-6 fatty acids 4.6 51.8
Ratio ω-6 / ω-3 0.07 52.2
Total SAFAa 6.4 12.8
Total MUFAb 16.4 29.5
Total PUFAc 69.5 53.2
aSAFA saturated fatty acid, bMUFA monounsaturated fatty acid, cPUFA
polyunsaturated fatty acid; Source: Hielm-Björman et al. (2012) [43], with a
few additions
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5,5′-dithiobis (2-nitro benzoic acid) in 0.1 M phosphate
buffer, pH 8.0, for non-protein thiols.
Concentrations of 8-hydroxy-2-deoxy Guanosine (8-
OH-dG) were measured in serum samples by an 8-
hydroxy-2-deoxy Guanosine EIA kit (Cayman Chemical,
Ann Arbor, MI, USA) to evaluate oxidative DNA dam-
age and used as an indicator of oxidative stress [54].
Serum free iron (NTBI) concentration was measured
by NTA-chelation/HPLC-based assay principally de-
scribed elsewhere [54, 55] and used as a surrogate
marker of iron metabolism and oxidation in the body.
Free carnitine (Free-Car) was measured using a Konelab
20XTi analyser (ThermoFisher Scientific, Vantaa, Finland)
and used as a marker of antioxidant capacity of the body.
Serum samples were pipetted to tubes (Centrifree
Amicon, Gloucestershire, UK), which were centrifuged at
2000 g for one hour. Clear supernatants were used in as-
says of free carnitine. For determination of total carnitine,
this supernatant was alkalized with 1 M NaOH. The incu-
bation time at 60 °C was one hour. After cooling the sam-
ple was acidified with 2 M HCl. This sample was used for
analysis of total carnitine. Carnitine reacted with
acetyl-CoA to form acetylcarnitine and CoA. Carni-
tine acetyltransferase was the catalyser in this reac-
tion. Free CoA reacted then with DTNB (5, 5-
dithiobis (2-nitro benzoicacid)). Forming a complex,
the thiophenolate ion was then measured at 405 nm.
The detection limit was 2.0 μmol/L.
Statistical analysis
All 77 intended-to-treat dogs were analysed. To calcu-
late differences within groups from baseline to end, a re-
peated samples T-test and Wilcoxon rank test were used
if the variables were normally distributed or not, respect-
ively. To test differences between groups at the different
evaluation times, an independent samples T-test or a
Mann-Whitney test was used, using the same criteria of
normality.
Results
Blood concentrations of fatty acids
Dogs were supplemented for 16 weeks with fish oil (N =
at start 39/at end 35) or corn oil (N = 38/36). No signifi-
cant differences between groups in terms of dogs per
group, gender, age, body weight or disease severity/body
distribution were observed [43].
As expected, serum concentrations of different fatty
acids reflected the fatty acid composition in the nutra-
ceutical products. All in all 69.5 % of the total fat con-
tent of the fish oil comprised PUFAs, whereof 63.6 %
omega-3 and 4.6 % omega-6 fatty acids. The fat content
of the corn oil had 52.8 % PUFAs, 1.0 % omega-3 and
51.8 % omega-6 fatty acids. The omega-6/omega-3 ratio
of the fish oil and the corn oil was 0.07 and 51.8, re-
spectively [43].
At the beginning of the trial, all dogs randomly distrib-
uted in either group had statistically similar blood
Baseline: 77 dogs met the inclusion criteria of OA 
diagnosis and pain severity by HCPI, were evaluated by
clinical examinations and had their blood collected at
day zero.
38 dogs were randomly assigned to compose the
group that received corn oil (placebo) for 16 
weeks
39 dogs were randomly assigned to compose
the group that received fish oil for 16 weeks
4 dogs were excluded during the period of
nutraceutical intervention due to owners’ 
decision (n = 3), and owner’s option for 
euthanasia (n = 1).*
End of the study at the 16th week: 35 dogs
from the fish oil group were analysed
2 dogs were excluded during the period of
nutraceutical intervention due to hemorraghic
enteritis (n = 1), and owner’s option for 
euthanasia (n = 1)*
End of the study at the 16th week: 36 dogs
from the corn oil group were analysed
Fig. 1 Flow chart showing the design and inclusion/exclusion criteria of the prospective study of fish oil as a nutraceutical intervention in dogs
suffering from osteoarthritis (OA). Corn oil was compared with fish oil as placebo. *Information on the dogs’ clinical follow up and pain outcome
are described by Hielm-Björkman et al. [43]
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concentrations of each evaluated fatty acid (Table 2).
The fatty acid blood concentrations at the end of the
trial showed that the dogs from each group had received
the intended nutraceutical product. The dogs that had
received fish oil exhibited a significant rise in blood
levels of the omega-3 fatty acids EPA, DPA and DHA
(all with P < 0.001) and a reduction in the concentra-
tions of omega-6 gamma-linolenic acid (GLA), AA
and linoleic acid (LA) (all with P < 0.001) and palmi-
toleic acid (PO) (P = 0.004) at 16 weeks. A significant
difference was also found in the blood concentrations
of the same fatty acids between dogs from the fish
and corn oil groups at the end of the trial, with dogs
in the former group having higher EPA, DPA and
DHA concentrations and lower GLA, AA and LA
concentrations (all with p ≤ 0.001).
Conversely, dogs in the corn oil group showed a sig-
nificant elevation in the blood concentrations of the
omega-6 fatty acids GLA (P = 0.018), AA (P = 0.030) and
LA (P = 0.007) and a decrease in omega-3 EPA (P <
0.001), DPA (P = 0.004) and DHA (P = 0.006) (Table 2).
Reductions in Palmitic acid (PA) (P = 0.002) and omega-
6 dihomogammalinolenic acid (DHGLA) (P = 0.011)
serum concentrations were also observed within the
corn oil group, but no significant difference was seen
in the comparison between supplement groups at the
end of the trial. The corn oil group showed higher
concentrations of omega-6 eicosadienoic acid EDA
(P = 0.044) at 16 weeks than the dogs that had re-
ceived fish oil. No side effects were reported or seen
in either group.
Blood cell counts and biochemical analytes
At baseline, all blood parameters were statistically simi-
lar among all dogs (Table 3). The haemograms revealed
some significant changes within and between the groups
of dogs receiving fish or corn oil from the beginning to
the end of the trial, although most values remained
within the reference ranges (Table 3). The Mean Cor-
puscular Haemoglobin (MCH) and the Mean Corpuscu-
lar Haemoglobin Concentration (MCHC) values were
slightly below the normal ranges and increased in dogs
from both groups (fish oil: P = 0.003 and P < 0.001, corn
oil: P < 0.001 and P < 0.001, respectively) during the 16-
week trial. A significant reduction in the Mean Corpus-
cular Volume (MCV) (P = 0.010) was found only within
the fish oil group. No significant difference was found in
the comparison between groups.
A significant reduction in monocyte counts in dogs
from both the fish oil (P < 0.001) and corn oil (P = 0.050)
groups between baseline and 16 weeks was observed.
Despite the reduction in monocyte percentage in both
groups, there was also a significant difference between
the groups (P = 0.030), so that the decrease was greater
in the fish oil group.
Basophil counts, obtained by manual counting, were
reduced significantly within the group of dogs receiv-
ing fish oil (P = 0.001) from the beginning to the end
of the study, but not within the corn oil group. The
comparison between groups also revealed that the
basophil counts were significantly lower in the fish oil
group (P = 0.012) than in the corn oil group at the
end of the trial.
Table 2 Blood concentrations of fatty acids at baseline and at 16 weeks in dogs receiving fish oil or corn oil supplementation
Variable Fish oil Corn oil Between groups
Baseline End of trial P-value/direction Baseline End of trial P-value/direction Baseline P-value End P-value
Fatty acids, %
PA, C16:0 15.44 ± 1.38 14.99 ± 1.88 0.191 14.99 ± 1.31 14.60 ± 1.28 0.002 ↓ 0.183 0.336
SA, C18:0 21.42 ± 1.49 21.38 ± 1.65 0.891 21.87 ± 1.62 21.85 ± 1.67 0.919 0.246 0.252
OLA, C18:1 ω-9 9.57 ± 1.43 9.43 ± 2.41 0.758 9.13 ± 1.23 8.90 ± 1.14 0.243 0.180 0.255
PO, C16:1 ω7 0.99 ± 0.35 0.85 ± 0.30 0.004 ↓ 0.91 ± 0.28 0.87 ± 0.25 0.407 0.339 0.739
LA, C18:2 ω-6 22.97 ± 2.36 20.91 ± 2.26 <0.001 ↓ 23.17 ± 2.60 24.13 ± 2.79 0.007 ↑ 0.743 <0.001b
GLA, C18:3 ω-6 0.19 ± 0.07 0.13 ± 0.05 <0.001 ↓ 0.17 ± 0.07 0.20 ± 0.10 0.018 ↑ 0.322 0.001b
EDA, C20:2 ω6 0.32 ± 0.09 0.31 ± 0.09 0.545 0.37 ± 0.08 0.36 ± 0.08 0.625 0.065 0.044b
DHGLA, C20:3 ω-6 0.88 ± 0.19 0.81 ± 0.27 0.111 0.95 ± 0.24 0.89 ± .25 0.011 ↓ 0.246 0.223
AA, C20:4 ω-6 19.48 ± 2.26 14.2 ± 2.06 <0.001 ↓ 19.48 ± 2.59 20.15 ± 2.51 0.030 ↑ 0.995 <0.001b
ALA, C18:3 ω-3 0.33 ± 0.11 0.31 ± 0.08 0.353 0.33 ± 0.14 0.34 ± 0.28 0.919 0.971 0.632
EPA, C20:5 ω-3 0.98 ± 0.48 6.81 ± 2.96 <0.001 ↑ 1.04 ± 0.44 0.70 ± 0.31 <0.001 ↓ 0.633 <0.001a
DPA, C22:5 ω-3 2.07 ± 0.45 3.11 ± 0.99 <0.001 ↑ 2.16 ± 0.62 1.96 ± 0.57 0.004 ↓ 0.529 <0.001a
DHA, C22:6 ω-3 1.52 ± 0.59 3.00 ± 1.04 <0.001 ↑ 1.56 ± 0.71 1.30 ± .50 0.006 ↓ 0.790 <0.001a
P-values for changes within and between groups; significant (P < 0.05) values bolded. aHigher values in the fish oil group; bHigher values in the corn oil group. See
Table 1 for fatty acid abbreviations. ↑ Value increased significantly; ↓ Value decreased significantly
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Table 3 Biomarkers for lipid metabolism, oxidation and inflammation; blood counts and biochemistry per group at start (baseline) and end (16 weeks) of fish oil or corn oil trial
Variable Fish oil Corn oil Between Groups
Baseline End of trial P-value/direction Baseline End of trial P-value/direction Baseline P-value End P-value
Oxidation marker
MDA (μmol/l) 3.41 ± 1.34 2.43 ± 0.92 <0.001 ↓ 3.41 ± 1.34 2.41 ± 1.01 0.001 ↓ 0.957 0.926
GSH (mmol/l) 1.97 ± 0.22 2.02 ± 0.17 0.200 2.01 ± 0.21 2.07 ± 0.22 0.184 0.645 0.296
8-OH-dG (pg/ml) 1.54 ± 0.60 1.64 ± 0.74 0.315 1.68 ± 0.60 1.75 ± 0.79 0.410 0.340 0.545
NTBI (μmol/l) −1.36 ± 4.11 −1.92 ± 2.58 0.248 −1.25 ± 2.17 −2.31 ± 1.64 0.002↓ 0.950 0.445
FCar (μmol/l) 18.18 ± 9.78 21.19 ± 9.58 0.004 ↑ 20.53 ± 9.78 22.23 ± 10.12 0.121 0.222 0.657
Haemograms (Unit) RV = Reference value
Haematocrit % RV = 38–57 50.15 ± 4.24 47.55 ± 8.95 0.096 49.22 ± 5.15 48.38 ± 5.88 0.237 0.729 0.881
Haemoglobin (g/l) RV = 140–203 164.23 ± 14.00 162.57 ± 15.19 0.453 160.41 ± 16.71 160.94 ± 19.23 0.816 0.616 0.409
MCV (fl) RV = 67–80 69.17 ± 2.15 68.73 ± 2.23 0.010 ↓ 69.90 ± 3.11 69.76 ± 2.54 0.636 0.339 0.180
MCH (pg) RV = 24–29 22.64 ± 0.77 22.88 ± 0.87 0.003 ↑ 22.76 ± 0.95 23.20 ± 0.97 <0.001 ↑ 0.572 0.494
MCHC (g/l) RV = 345–367 327.33 ± 3.96 332.80 ± 5.93 <0.001 ↑ 325.81 ± 6.18 332.56 ± 6.79 <0.001 ↑ 0.379 0.364
Platelet (n × 109/l) RV = 102–395 304.76 ± 88.37 309.83 ± 98.56 0.692 316.13 ± 93.83 288.41 ± 101.68 0.029 ↓ 0.991 0.513
RBC (n × 1012/l) RV = 5.3–8.0 7.25 ± 0.61 7.11 ± 0.74 0.198 7.04 ± .76 6.94 ± 0.84 0.319 0.474 0.291
WBC (n × 109/l) RV = 5.4–17.4 8.37 ± 2.27 8.20 ± 2.36 0.564 8.45 ± 3.22 8.51 ± 3.31 0.913 0.712 0.975
Neutrophil % RV = 40–80 68.97 ± 10.52 66.46 ± 14.40 0.350 69.89 ± 11.30 70.56 ± 8.44 0.644 0.971 0.195
Lymphocyte % RV = 10–36 18.10 ± 8.61 19.68 ± 7.74 0.109 16.11 ± 7.20 16.82 ± 5.88 0.482 0.504 0.166
Monocyte % RV = 0–13 3.84 ± 2.50 1.77 ± 1.92 <0.001 ↓ 4.11 ± 3.02 3.06 ± 2.70 0.050 ↓ 0.340 0.030a
Eosinophil % RV = 2–10 7.59 ± 3.53 9.01 ± 4.79 0.069 8.54 ± 5.33 8.42 ± 6.00 0.927 0.605 0.551
Basophil % RV = 0–1 1.47 ± 1.22 0.62 ± 0.62 0.001 1.33 ± 1.08 1.13 ± 0.96 0.396 0.882 0.012a
Blood biochemistry
Urea (mmol/l) RV = 2.4–8.8 5.23 ± 1.61 5.48 ± 1.31 0.308 5.12 ± 1.37 5.25 ± 1.80 0.695 0.430 0.536
Creatinine (μmol/l) RV = 57–116 86.85 ± 9.36 90.65 ± 11.73 0.008 ↑ 88.62 ± 13.34 93.51 ± 14.85 0.001 ↑ 0.372 0.311
ALP (U/l) RV = 33–215 127.83 ± 143.75 146.85 ± 170.32 0.052 147.32 ± 107.88 153.70 ± 116.36 0.283 0.598 0.843
ALT (U/l) RV = 18–77 52.35 ± 24.24 77.22 ± 136.25 0.279 58.60 ± 26.96 58.12 ± 28.77 0.888 0.452 0.414
Albumin (g/l) RV = 30–41 33.68 ± 2.02 33.77 ± 2.57 0.790 32.80 ± 2.39 33.24 ± 2.51 0.160 0.129 0.385
Total protein (g/l) RV = 58–77 63.53 ± 4.07 64.42 ± 4.34 0.158 63.97 ± 3.18 64.50 ± 3.59 0.469 0.990 0.932
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Table 3 Biomarkers for lipid metabolism, oxidation and inflammation; blood counts and biochemistry per group at start (baseline) and end (16 weeks) of fish oil or corn oil trial
(Continued)
Glucose (mmol/l) RV = 4.0–6.4 5.22 ± 0.38 5.34 ± 0.43 0.171 5.18 ± 0.37 5.32 ± 0.47 0.041 ↑ 0.645 0.854
Cholesterol (mmol/l) RV = 3.7–9.8 6.51 ± 1.90 6.94 ± 2.40 0.109 7.13 ± 1.62 7.73 ± 2.03 0.011 ↑ 0.463 0.135
Triglycerides (mmol/l) RV = 0.5–1.1 0.79 ± 0.37 0.71 ± 0.46 0.406 0.80 ± 0.31 0.81 ± 0.36 0.854 0.299 0.335
MCV Mean Corpuscular Volume, MCH Mean Corpuscular Haemoglobin, MCHC Mean Corpuscular Haemoglobin Concentration, RDW Red Cell Distribution Width, RBC Red Blood Cell Count, WBC White Blood Cell Count,
ALP Alkaline Phosphatase, ALT Alanine Aminotransferase. P-values for changes within and between groups; significant (P < 0.05) values bolded. aLower counts in the Fish oil group; bHigher values in the Corn oil group.
RV Reference value. ↑ Value increased significantly; ↓ Value decreased significantly
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The platelet counts were significantly reduced within
the corn oil group (P = 0.029) from the beginning to the
end of the study. By contrast, in the fish oil group the
platelets were increased, albeit not significantly.
The creatinine values increased in the serum of dogs
from both groups (fish oil: P = 0.008, corn oil: P = 0.001)
from the beginning to the end of the study. The final
mean creatinine value was higher in the corn oil group,
although the difference was not significant.
The group of dogs that received corn oil presented a
significant elevation in serum values of glucose (P =
0.041) and cholesterol (P = 0.011), whereas the increases
in the fish oil group were not significant. At the end of
the trial, no statistical difference emerged between
groups for either glucose or cholesterol serum values.
Oxidative stress markers
The biomarkers that were chosen to reflect oxidative
stress (MDA, 8-OH-dG and NTBI) and antioxidant cap-
acity of the body (GSH and Free-Car) were statistically
similar in the two dog groups at the beginning of the
trial (Table 3). MDA values exhibited a significant reduc-
tion in dogs within both groups (fish oil: P < 0.001, corn
oil: P = 0.001) from the beginning to the end of the trial.
The comparison between groups did not reveal a statis-
tical difference at the end of the study.
Serum values for 8-OH-dG exhibited a discrete and
non-significant elevation within both groups. When
these values were compared between groups, the mean
value for the corn oil group was slightly higher than for
the fish oil group, although the difference did not reach
significance.
Serum free iron, in the form of non-transferrin bound
iron (NTBI), resulted in negative values. Concentrations
were higher among dogs receiving corn oil than among
those receiving fish oil. The values for serum NTBI ex-
hibited a decrease in both groups, but the reduction was
significant only in the corn oil group (P = 0.002). No sig-
nificant difference was found between groups at the end
of the trial.
Blood GSH (mg/L) mean values exhibited minor (non-
significant) elevations within both groups from the be-
ginning to the end of the trial. The comparison between
groups also did not reveal significant differences at the
end of the trial.
Serum Free-Car values increased in both dog groups
from the beginning to the end of the trial, but the differ-
ence was significant only in dogs within the fish oil
group (P = 0.004). No difference was found between
groups at any time.
Discussion
Dietary supplementation of dogs suffering from OA with
fish oil and corn oil clearly resulted in changes in blood
concentrations of fatty acids, reflecting the fatty acid
composition of the supplements. In a previous study, au-
thors have reported a similar effect on blood profile of
fatty acids in healthy dogs undergoing dietary trials with
standard fish and corn oils [56]. Thus, the usage of oils
for nutraceutical purposes, by the oral route, will
promptly promote the bioavailability of fatty acids to the
target tissues via the bloodstream. Both oils used in the
trials were well tolerated and did not produce any ad-
verse effects in the dogs over the 16 weeks; neither in
clinical follow-up, haemograms or serum biochemistry
for liver and renal function.
So far, the best clinical tools to definitively diagnose,
classify and define disease progression or prognosis of OA
in dogs are radiography, pain intensity measurements and
functional assessments [57]. Nevertheless, such methods
are sensitive only when the disease reaches an advanced
stage, often with irreversible lesions in cartilage and bone
[58]. A number of potential biomarkers have been studied
to aid diagnosis, particularly in the early phase, and con-
sensus exists that combined molecules could be applied
for the assessment of disease outcome after the use of
disease-modifying drugs [58]. A lipidomic approach has
suggested that lipid metabolism can be altered during the
course of OA in people, and an association between AA
release from phospholipids due to an increased activity of
phospholipase A2 (PLA2) and inflammatory pain has been
described [59]. At least one clinical study has shown a re-
lation between higher blood concentrations of AA, higher
blood concentrations of omega-6 PUFAs and synovitis in
patients with OA [39].
In this study in dogs, supplement-related changes in
the serum fatty acid profile also influenced the associ-
ated metabolites. Fish oil supplementation induced a re-
duction in the serum concentration of LA and therefore
also in the metabolites GLA, DHGLA and AA. Although
the fish oil preparation used in our study contained 2 %
AA, there was a pronounced decrease in serum AA con-
centration in the fish oil-supplemented dogs. A decrease
in the AA concentration is a result of competition be-
tween AA and long-chain omega-3 PUFA for incorpor-
ation into circulating blood and tissue phospholipids
[60]. Similar changes over a long period would be ex-
pected also in the phospholipids of other cells’ mem-
branes. Long-chain PUFA omega-3 fatty acids (EPA,
DPA and DHA) increased among serum total lipids,
consistent with their concentrations in the supplemented
fish oil. Supplementation with corn oil increased the LA
content among serum total lipids and produced small
but consistent increases in LA’s metabolites (EDA, GLA,
DHGLA and AA). Although there was a significant dif-
ference in omega-6 EDA between the two groups at the
end of the trial, this seems to be mostly due to the near-
difference between the two groups already at baseline.
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EDA was also shown to be able to modulate the metab-
olism of PUFAs and alter the responsiveness of macro-
phages toward inflammatory stimulation [61]. However,
the amelioration of functional parameters in both groups
of dogs seen in the clinical data published earlier [43]
suggests that not only the fish oil but also the corn oil
produces some beneficial effect on the pathological con-
dition. Despite not always reaching statistical signifi-
cance, the global results of clinical and functional tests
[43], together with the laboratory data obtained in this
study, indicate a more consistent improvement in the
dogs receiving fish oil than in the ones receiving corn
oil. But, no substantial global difference between the two
groups was seen.
Because EPA metabolism in cell membranes results in
less pro-inflammatory eicosanoids, namely 3-series pros-
taglandins and 5-series leukotrienes, than the respective
2-series and 4-series derived from AA metabolism, these
omega-3 fatty acids have been considered anti-
inflammatory [18]. The anti-inflammatory properties
attributed to omega-3 PUFAs that are potentially re-
sponsible for healing articular structures, cells, and mol-
ecules whose metabolism is affected by OA include
reduction of proteoglycan-degrading enzymes, COX-2,
and inflammatory cytokines IL-1 and TNF-α, as shown
in vitro [45]. There is a need to prove these effects in
clinical studies with fish oil products used as nutraceut-
ical compounds to treat OA of companion animals [62,
63] and humans [5, 39]. In the dogs whose samples were
analyzed here, the evaluated clinical outcome measures
reflecting joint function and pain improved in the group
receiving fish oil, whereas only pain improved in the
corn oil group [43].
Changes in the diagnostic markers of oxidation (MDA,
NTBI and 8-OH-dG) indicate a reduced concentration
of oxidation in the fish oil group and suggest a possible
effect of EPA and DHA on oxidative damage in tissue
lipids. EPA and DHA might have acted as antioxidants
or boosted the endogenous antioxidant mechanisms.
The exact mechanism of action by which fish oil can
regulate the level of plasma and tissue diagnostic marker
enzymes in OA condition is unclear. Despite scant
knowledge based on in vivo models, it is believed that
dietary omega-3 PUFA stabilizes cell membranes by
modulating the lipid environment [64], thereby making
it less susceptible to damage caused by inflammatory
agents. Concerning the oxidative stress molecules in-
volved in OA, our findings of decreased MDA serum
concentrations in all dogs may indicate that a similar de-
gree of protection against lipid peroxidation was con-
ferred by both fish and corn oil. Osteoarthritis is
believed to be caused by mechanical stress on the joint
leading to low grade inflammatory processes [7]. ROS
are key components of many normal physiological
processes that, at moderate levels, act as indispensable
second messengers. However, higher than normal intra-
cellular ROS concentrations can still overpower the
homeostatic proteins and cause oxidative damage to the
cell and contribute to the onset and progression of OA
by inducing chondrocyte death and matrix degradation
[65]. It has been shown that MDA, as a marker of lipid
peroxidation, is increased in inflamed cartilage tissue
and synovial fluid [23, 28, 66] as well as in blood of
humans [29, 67] and dogs [32] suffering from OA. In
vitro assays have demonstrated cartilage degradation
mediated by lipid peroxidation [8]. On the other hand,
the possibility of a heightened risk of lipid peroxidation
after using fish oil has also been emphasized in a recent
review [18], but was not confirmed here. Another study
has demonstrated that fish oil decreased MDA levels in
healthy dogs [68]. The slight elevation in values of 8-
OH-dG that we found in both fish and corn oil groups
was non-significant and fell below the reported plasma
values for healthy dogs [69]. It indicates that during the
study period the dogs did not exhibit evidence of DNA
damage detected by measuring 8-OH-dG either before
or after receiving fish or corn oil. In humans, elevations
of 8-OH-dG have been reported in diverse conditions,
including rheumatoid arthritis [70]. However, some au-
thors consider 8-OH-dG measurement from the blood
to be a questionable marker of oxidative stress, empha-
sizing the need for more research [71]. We suggest that
the same is true for veterinary medicine, given the scar-
city of reports on 8-OH-dG measurements in dogs. In
any case, the results described herein contribute to the
research, confirming that supplementation with fish oil,
and even with corn oil, is significantly associated with
decreased concentrations of lipid peroxidation products,
namely MDA, in the plasma of OA dogs. Moreover, no
evidence for lipid peroxidation emerged with the com-
bined assays used in this study. Other authors have dem-
onstrated that fish oil, which is rich in omega-3 PUFA,
decreases the production of inflammatory series of
prostaglandins and cytokines [72]. Our results indicate
reduced oxidative stress markers in OA dogs supple-
mented with dietary oils, perhaps involving an equivalent
mechanism, boosting the antioxidant defence in vivo.
Thus, it can be assumed that dietary fish oil might en-
hance the antioxidant capability by inhibiting the forma-
tion of pro-inflammatory mediators or by upregulating
the activities of other enzymes directly or indirectly as-
sociated with the antioxidant system.
The reduction of serum free iron that we found in the
corn oil group (significant reduction) and in the fish oil
group (non-significant) suggests at least a less favourable
metabolic environment for oxidative damage. Presence
and accumulation of iron has been reported to facilitate
the formation of ROS, such as the hydroxyl radical,
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which is the most important radical in 8-OHdG produc-
tion [54, 73]. The forms of free iron include non-
transferrin bound iron (NTBI) [74]. An excess of
intercellular free iron causes cell damage by catalysing
the production of the hydroxyl radical through the Fen-
ton reaction [75, 76]. Thus, excessive free iron could be
a reliable parameter of iron toxicity [75, 77]. Evidence
has suggested that oxygen free radicals, especially ones
promoted by free iron, play an important role in the de-
velopment of diseases [75, 77]. Free iron can damage tis-
sues by catalysing the conversion of hydrogen peroxide
to free radical ions that attack lipids, proteins and
DNA [75, 78]. Fish and corn oil, as seen in the
present study, may have played a protective role
against increased free iron, possibly through iron
binding and export, thus preventing iron-induced tox-
icity via the Fenton reaction [76].
The results obtained for blood measurements of GSH
and Free-Car indicate that both oils were capable of
maintaining the integrity of the antioxidant defence sys-
tem. Moreover, fish oil supplementation induced a sig-
nificant rise in blood concentrations of Free-Car. L-
carnitine protects cells against oxidative damage since it
acts as a free radical scavenger and has an important
function in lipid metabolism by transporting fatty acids
across the inner mitochondrial membrane [79]. Abun-
dant evidence indicates the importance of GSH in main-
taining the antioxidant homeostasis in cartilage and
during articular pathological conditions [23, 27, 29, 67,
80–83]. Glutathione is a tripeptide (y-Glutamyl-cystei-
nyl-glycine) thiol present in virtually all animal cells – in
normal conditions, both the reduced (GSH) and oxi-
dized (GSSG) forms of glutathione remain in a balanced
state [53]. GSH acts as a free radical scavenger and neu-
tralizes superoxides, peroxide radicals and singlet oxygen
by donating hydrogen atoms [84]. Antioxidant enzymes
like glutathione S-transferase (GST) and glutathione per-
oxidase (GPX) utilize reduced forms of GSH to carry
out their scavenging and detoxification activities, and at
the end of the process, an oxidized form of GSSG is the
final product [85]. Kumar and Das [86] reported a higher
concentration of glutathione in rats with Freund’s adju-
vant (CFA)-induced inflammation that were treated with
fish oil. Arab et al. [87] noted that DHA enhanced the
cellular GSH concentration by elevating the activities of
gamma-glutamyl-cysteinyl ligase and glutathione reduc-
tase enzymes. PUFAs were reported to enhance the
activity of glutathione reductase [88] and glucose-6-
phosphate dehydrogenase enzymes [89], which in turn
can restore GSH at a faster rate.
So far, a number of clinical studies have shown sys-
temic evidence of a reduced antioxidant defence system,
including reduced blood concentrations of GSH, in the
course of inflammatory articular diseases in humans
[90–93]. Although the blood values for GSH were within
the reference values for dogs [94] before the trial in dogs
with OA, we observed elevated values after 16 weeks of
oil supplementation. Thus, we attribute these elevations
to the supplementation with either fish oil or corn oil.
The increase in GSH may be beneficial since it was con-
current with a reduction of MDA in both groups of
dogs. In fact, it has been shown in dogs that GSH has an
important role in adequate lipid peroxide detoxification
during illness [94]. In the literature on canine OA, how-
ever, the only report on blood markers of oxidative stress
associated with the disease was in a study using an ex-
perimental Pond-Nuki model [30]. As far as we know,
no studies exist on oxidative and antioxidant parameters
in naturally occurring canine OA, apart from the results
reported here. Moreover, our study shows inedited re-
sults of the effect of supplementation with fish and corn
oil on the oxidative/antioxidant balance in natural occur-
ring canine OA. Nonetheless, further research should in-
clude analyses of serum isoprostane and prostaglandin
as markers of oxidation and inflammation. In our study,
limited biological samples were available.
The results of blood biochemistry, all within the nor-
mal range, support the conclusion that 16-week supple-
mentation with fish or corn oil was not associated with
toxicity or metabolic imbalance in dogs. Although
hyperglycaemia was listed as a potential adverse effect of
fish oil supplementation of dogs [18], we found no evi-
dence of such an effect. In fact, the glucose concentra-
tions were significantly higher within the corn oil group
after 16 weeks of supplementation, although no signifi-
cant difference was seen between the two groups. More-
over, all values remained within the reference range.
Similarly, the cholesterol concentrations were signifi-
cantly higher in the dogs after receiving corn oil, but not
fish oil, but at the end of the 16-week trial they
remained within normal reference values. These are in
tune with a recent study where fish oil supplementation
increased plasma triglycerides and ghrelin but did not
appear to affect protein metabolism or postprandial gly-
caemia in adult lean dogs, whereas an increase in choles-
terol concentration could be seen in the control diet
group [95].
Concerning haematology tests, most values stayed
within references for the dogs in our study. Administra-
tion of fish or corn oil during 16 weeks caused no
change in blood haemoglobin concentration, although
significant elevations of MCH and MCHC were seen in
both groups from baseline to the end of the trial. The
elevation of haemoglobin concentration within cells in
both groups of dogs may be attributed to the fact that
the mean values were at the lower end of the reference
range at the beginning of the study. Thus, the oils seem
to have enhanced haemoglobin synthesis towards
Barrouin-Melo et al. Lipids in Health and Disease  (2016) 15:139 Page 11 of 16
normality during the 16-week study. There are no simi-
lar or comparable reports in dogs in the literature. In
humans, there are reports of haemoglobin reduction in
healthy individuals [96] and no change in patients with
risk of anaemia after supplementation with fish oil [97, 98].
Likewise, we observed a significant reduction of the MCV
values within the fish oil group, but comparable changes in
dogs were not found elsewhere; also, no statistical differ-
ence was observed between groups. Elevations in packed
cell volume after ingestion of fish oil for six weeks have
been reported in healthy human beings [96], and no differ-
ence were found in patients with risk of anaemia [97]. The
leucocyte counts of dogs in the present study revealed a sig-
nificant reduction in the number of monocytes and baso-
phils in the group receiving fish oil, from baseline to the
end of the trial. These changes were also significant in the
comparison with the dogs receiving corn oil over the same
period. However, all counts, including those for other white
cells, remained within reference values for dogs. Changes in
eicosanoid expression towards the generation of leu-
kotriene B5 induced by EPA ingestion have been
speculated not to promote differences in circulating
leucocyte counts in humans [99], although at least
one study has shown increases in total leucocyte and
monocyte counts after fish oil supplement [96]. It has
also been shown that omega-3 fatty acids are able to
interfere with leucocyte chemotaxis, adhesion mol-
ecule expression and leucocyte-endothelial adhesive
interactions [60], the effect of which, attributed to the
decrease of AA content of cells involved in immune
responses, is associated with clinical improvement of
inflammatory diseases including rheumatoid arthritis
[100]. Even though a higher ratio of leukotriene B5/
B4 has been reported in dogs supplemented with fish
oil than in dogs given corn oil [17], no information
on leucocyte counts in studies with fish oil supple-
mentation of healthy dogs or dogs with OA was earl-
ier available in the literature. A clinical study in dogs
has, however, shown that the concentration of leuko-
triene B4 in osteoarthritic hip joint capsules was
higher than in clinically normal ones [101]. Still, ex-
tensive and recent reviews on the therapeutic use of
fish oil for animal diseases, including OA, do not
mention its impact on haemograms [62].
The platelet counts in the present study showed that
supplementation with corn oil resulted in lowered circu-
lating numbers from the beginning to the end of the 16-
week trial and that fish oil ingestion was associated with
a non-significant elevation of platelets during the same
period. Nevertheless, the values remained within the
normal ranges for dogs in both groups, and the compari-
son between groups at the end of the trial showed negli-
gible and non-significant differences. No bleeding events
occurred during the clinical follow-up of the dogs.
Although altered platelet function has been considered a
potential risk of fish oil supplementation in dogs, a re-
cent review concluded that there is no evidence of a
harmful effect on platelet function or counts or clinical
consequences due to fish oil or its fatty acids [18].
From our observations of both dog groups, we can
hypothesize that the oils, particularly the fish oil given to
the dogs as a supplement seemed to have promoted an
abundance of beneficial polyunsaturated DHA and EPA,
thus altering the availability of certain fatty acids in the
body. At the cell membrane level, these fatty acids could
have facilitated the repair of mitochondrial and other
membranes, which could have been damaged by ROS
due to inflammation in OA. As depicted by the signifi-
cantly elevated concentrations of carnitine and reduced
concentrations of MDA within the group of dogs that
received fish oil, these fatty acids may also have pro-
moted a better state of redox regulation. Clinically, the
favourable shift in the membrane composition of lipids
would be related to the reduction of pain and lameness
indicators described in the dogs [43]. As OA often has a
neuropathic aspect when chronic, the ROS contribution
might be even more pronounced clinically at later stages:
Neurons are especially sensitive to ROS since neurons
have greater energy demands to function as compared to
glial and other cells in the central nervous system [102,
103]. Also lipid peroxidation products may contribute to
neuropathic pain in OA as they have been shown to
contribute to neuropathic pain in chronic spinal cord in-
jury animals [104]. However, the mechanism that ROS
and lipid peroxidation play in chronic neuropathic pain
is not well understood.
When the organism has more beneficial fatty acids it be-
comes less prone to peroxidation. For therapeutic use, a
recent review has discussed and clarified the basis for
what the authors called Lipid Replacement Therapy, in
which membrane lipids can be replaced by, among others,
oral supplements, promoting therapeutic effects on differ-
ent diseases [105]. As well, Scicchitano et al. (2012) have
reviewed and proposed an important role for nutraceuti-
cals, including fish oils, in the control of lipid metabolism
thus improving the overall burden of oxidation of lipids
[106]. In the present study, fish oil supplementation seems
to have promoted such effects, and corn oil to a lesser ex-
tent [43]. Considering that OA is a chronic disease whose
clinical presentation takes longer than the actual onset of
pathological symptoms, our results suggest that a longer
follow-up would maybe have allowed clearer differences
to emerge. In the future, the extent to which fish oil modi-
fies the redox balance in healthy dogs and dogs with OA
should be evaluated. Future fish oil supplementation study
groups should also be stratified according to if they have a
neuropathic aspect of pain. Further, one should consider
another control substance than corn oil.
Barrouin-Melo et al. Lipids in Health and Disease  (2016) 15:139 Page 12 of 16
Conclusion
In global terms, there was no clear difference between
dogs fed fish oil or corn oil. The oxidative status markers
indicated a decrease in oxidative stress (MDA and iron)
and an increase in antioxidant capacity (Free-Car and
GSH) both in dogs receiving fish oil and corn oil. The
elevation of the antioxidant capacity and the decrease of
inflammatory monocytes and basophils were, however,
more significant in the fish oil group and are unprece-
dented results reported in dogs with OA. Despite the
fact that values remained within the normal range, chol-
esterol and glucose increased significantly only in the
corn oil group.
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